Patrick W G Mallon

Summary

Affiliation: University of New South Wales
Country: Australia

Publications

  1. ncbi request reprint Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Antivir Ther 10:M101-8. 2005
  2. ncbi request reprint Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
  3. ncbi request reprint In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    J Infect Dis 191:1686-96. 2005
  4. doi request reprint Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
  5. pmc HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy
    Allison Martin
    The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e77138. 2013
  6. ncbi request reprint Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005
  7. ncbi request reprint The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 44:1475-83. 2007
  8. pmc Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
    Allison Martin
    aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint Louis, Paris, France
    AIDS 27:2403-11. 2013
  9. ncbi request reprint Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
    J Antimicrob Chemother 56:380-7. 2005
  10. ncbi request reprint Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 38:156-62. 2005

Detail Information

Publications17

  1. ncbi request reprint Methodological considerations in human studies of gene expression in HIV-associated lipodystrophy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Antivir Ther 10:M101-8. 2005
    ..Careful collection and processing of adequate biological samples, robust laboratory processes and assays, and appropriate study design can help overcome many of these difficulties...
  2. ncbi request reprint Effect of pravastatin on body composition and markers of cardiovascular disease in HIV-infected men--a randomized, placebo-controlled study
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst, Sydney, NSW 2010, Australia
    AIDS 20:1003-10. 2006
    ..To determine the effect of the 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor, pravastatin, on markers of cardiovascular risk and lipodystrophy in HIV-infected, protease inhibitor (PI)-treated men with hypercholesterolaemia...
  3. ncbi request reprint In vivo, nucleoside reverse-transcriptase inhibitors alter expression of both mitochondrial and lipid metabolism genes in the absence of depletion of mitochondrial DNA
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, NSW 2010, Australia
    J Infect Dis 191:1686-96. 2005
    ..The effects of this mitochondrial dysfunction on lipid metabolism, at a molecular level in vivo, have not been described...
  4. doi request reprint Effect of rosiglitazone on peroxisome proliferator-activated receptor gamma gene expression in human adipose tissue is limited by antiretroviral drug-induced mitochondrial dysfunction
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Australia
    J Infect Dis 198:1794-803. 2008
    ..Rosiglitazone (RSG), a PPARgamma agonist, improves congenital lipoatrophy but not HIV lipoatrophy...
  5. pmc HIV lipodystrophy in participants randomised to lopinavir/ritonavir (LPV/r) +2-3 nucleoside/nucleotide reverse transcriptase inhibitors (N(t)RTI) or LPV/r + raltegravir as second-line antiretroviral therapy
    Allison Martin
    The Kirby Institute, University of New South Wales, Sydney, New South Wales, Australia
    PLoS ONE 8:e77138. 2013
    ....
  6. ncbi request reprint Influence of rosiglitazone on flow-mediated dilation and other markers of cardiovascular risk in HIV-infected patients with lipoatrophy
    Jason C Kovacic
    Cardiology Department, HIV, Immunology and Infectious Diseases Clinical Services Unit, St Vincent s Hospital, Sydney, Australia
    Antivir Ther 10:135-43. 2005
    ..This study sought to investigate the effects of rosiglitazone on endothelial function and other markers of cardiovascular risk in patients with HIV-related lipoatrophy...
  7. ncbi request reprint The safety, efficacy, and pharmacokinetic profile of a switch in antiretroviral therapy to saquinavir, ritonavir, and atazanavir alone for 48 weeks and a switch in the saquinavir formulation
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, Australia
    Clin Infect Dis 44:1475-83. 2007
    ..Ritonavir-boosted double-protease inhibitor (PI)-only regimens are such an option but are prone to pharmacokinetic interactions...
  8. pmc Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy
    Allison Martin
    aThe Kirby Institute, University of New South Wales, Sydney, Australia bUCD School of Medicine and Medical Science, Dublin, Ireland cThe Alfred Hospital, Melbourne, Australia dCICAL, Buenos Aires, Argentina eThai Red Cross AIDS Research Center, Bangkok, Thailand fHopital Saint Louis, Paris, France
    AIDS 27:2403-11. 2013
    ....
  9. ncbi request reprint Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy
    Alan Winston
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Sydney, 2010, Australia
    J Antimicrob Chemother 56:380-7. 2005
    ..The aim of this study was to assess the clinical associations with plasma atazanavir concentrations in HIV-positive individuals...
  10. ncbi request reprint Buffalo hump seen in HIV-associated lipodystrophy is associated with hyperinsulinemia but not dyslipidemia
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, University of New South Wales, Sydney, Australia
    J Acquir Immune Defic Syndr 38:156-62. 2005
    ....
  11. ncbi request reprint Therapeutic approaches to combating lipoatrophy: do they work?
    Allison Martin
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, 376 Victoria St, Darlinghurst NSW 2010, Sydney, Australia
    J Antimicrob Chemother 55:612-5. 2005
    ....
  12. ncbi request reprint Pathogenesis of lipodystrophy and lipid abnormalities in patients taking antiretroviral therapy
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, Level 2, St Vincent s Medical Centre, St Vincent s Hospital, Sydney, Darlinghurst, NSW 2010, Australia
    AIDS Rev 9:3-15. 2007
    ..This review will summarize what is known of the molecular mechanisms underlying HIV-associated lipodystrophy. A greater understanding of these mechanisms is essential if effective therapeutic options are to be found...
  13. ncbi request reprint 11th Conference on Retroviruses and Opportunistic Infections, San Francisco, 8-11 February 2004: where are the breakthroughs?
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, 376 Victoria Street, Darlinghurst 2010, Sydney, Australia
    J HIV Ther 9:19-22. 2004
  14. ncbi request reprint HIV-associated lipodystrophy: description, pathogenesis, and molecular pathways
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, St Vincent s Hospital Medical Centre, 376 Victoria Street, Sydney NSW 2010, Australia
    Curr Diab Rep 2:116-24. 2002
    ..Treatment strategies, normally successful in the general population, have generally been less effective in this group of people, in which the detrimental effects of the antiretroviral medications are ongoing...
  15. pmc Antiretroviral therapy and dyslipidaemia: unlocking the code
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, University of New South Wales, St Vincent s Medical Centre, Sydney, Australia unsw edu au
    PLoS Med 3:e85. 2006
  16. ncbi request reprint Effect of therapeutic drug monitoring on outcome in antiretroviral experienced HIV-infected individuals
    Patrick W G Mallon
    National Centre in HIV Epidemiology and Clinical Research, Faculty of Medicine, St Vincent s Hospital Medical Centre, University of New South Wales, 376 Victoria Street, Sydney NSW 2010, Australia
    J Clin Virol 26:223-7. 2003
    ..Nevertheless, it has a potentially important role to play in the management of HIV-infected patients, with the aim of limiting toxicity, optimising antiviral effect and decreasing virological failure and emergence of viral resistance...
  17. doi request reprint Ritonavir-boosted atazanavir, methadone, and ventricular tachycardia: 2 case reports
    David P Gallagher
    Department of 1Infectious Diseases, Mater Misericordiae University Hospital, University College Dublin, Dublin, Ireland
    Clin Infect Dis 47:e36-8. 2008
    ..Discontinuation of atazanavir in both cases resulted in a reduction in the QT interval and cessation of arrhythmia. We concluded that atazanavir contributed to prolonged corrected QT interval and subsequent ventricular tachycardia...